Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders

Nutrients. 2023 Nov 13;15(22):4772. doi: 10.3390/nu15224772.

Abstract

Lipid metabolic diseases have substantial morbidity and mortality rates, posing a significant threat to human health. PPARα, a member of the peroxisome proliferator-activated receptors (PPARs), plays a crucial role in lipid metabolism and immune regulation. Recent studies have increasingly recognized the pivotal involvement of PPARα in diverse pathological conditions. This comprehensive review aims to elucidate the multifaceted role of PPARα in metabolic diseases including liver diseases, diabetes-related diseases, age-related diseases, and cancers, shedding light on the underlying molecular mechanisms and some regulatory effects of natural/synthetic ligands of PPARα. By summarizing the latest research findings on PPARα, we aim to provide a foundation for the possible therapeutic exploitation of PPARα in lipid metabolic diseases.

Keywords: PPARα; cancer; cell senescence; diabetes-related diseases; lipid metabolism; metabolic disorders.

Publication types

  • Review

MeSH terms

  • Humans
  • Lipid Metabolism
  • Lipid Metabolism Disorders*
  • Lipids
  • Metabolic Diseases* / drug therapy
  • PPAR alpha / metabolism
  • Receptors, Cytoplasmic and Nuclear / metabolism

Substances

  • PPAR alpha
  • Receptors, Cytoplasmic and Nuclear
  • Lipids